Zeb1 promotes androgen independence of prostate cancer via induction of stem cell-like properties

Experimental Biology and Medicine

Volumn 239, Issue 7, 2014, Pages 813-822

  Li, Ping ^a   Wang, Jia ^b   Chu, Mingliang ^a   Zhang, Kaiqing ^b   Yang, Ru ^a   Gao, Wei Qiang ^a,b  

^a School of Medicine   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

androgen independent prostate cancer; cancer stem cells; epithelial mesenchymal transition; Zeb1

Indexed keywords

BICALUTAMIDE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ANDROGEN DEPRIVATION THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASTRATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; WOUND HEALING;

EID: 84904887963     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370214538727     Document Type: Article

References (15)

1. Roth BJ.New therapeutic agents for hormone-refractory prostate cancer.Semin Oncol. 1996;23:49-55.
2. Sun Y,Wang BE,Leong KG,Yue P,Li L,Jhunjhunwala S,Chen D,Seo K,Modrusan Z,Gao WQ,Settleman J,Johnson L.Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.Cancer Res. 2012;72:527-36.
3. Chaffer CL,Marjanovic ND,Lee T,Bell G,Kleer CG,Reinhardt F,D'Alessio AC,Young RA,Weinberg RA.Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity.Cell. 2013;154:61-74.
4. Wellner U,Schubert J,Burk UC,Schmalhofer O,Zhu F,Sonntag A,Waldvogel B,Vannier C,Darling D,Zur HA,Brunton VG,Morton J,Sansom O,Schuler J,Stemmler MP,Herzberger C,Hopt U,Keck T,Brabletz S,Brabletz T.The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs.Nat Cell Biol. 2009;11:1487-95.
5. Mulholland DJ,Kobayashi N,Ruscetti M,Zhi A,Tran LM,Huang J,Gleave M,Wu H.Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells.Cancer Res. 2012;72:1878-89.
6. Marchiani S,Tamburrino L,Nesi G,Paglierani M,Gelmini S,Orlando C,Maggi M,Forti G,Baldi E.Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation.Int J Androl. 2010;33:784-93.
7. Russell PJ,Kingsley EA.Human prostate cancer cell lines.Methods Mol Med. 2003;81:21-39.
8. Wang S,Gao J,Lei Q,Rozengurt N,Pritchard C,Jiao J,Thomas GV,Li G,Roy-Burman P,Nelson PS,Liu X,Wu H.Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.Cancer Cell. 2003;4:209-21.
9. Lapointe J,Li C,Higgins JP,van de Rijn M,Bair E,Montgomery K,Ferrari M,Egevad L,Rayford W,Bergerheim U,Ekman P,DeMarzo AM,Tibshirani R,Botstein D,Brown PO,Brooks JD,Pollack JR.Gene expression profiling identifies clinically relevant subtypes of prostate cancer.Proc Natl Acad Sci USA. 2004;101:811-16.
10. Wallace TA,Prueitt RL,Yi M,Howe TM,Gillespie JW,Yfantis HG,Stephens RM,Caporaso NE,Loffredo CA,Ambs S.Tumor immunobiological differences in prostate cancer between African-American and European-American men.Cancer Res. 2008;68:927-36.
11. Mani SA,Guo W,Liao MJ,Eaton EN,Ayyanan A,Zhou AY,Brooks M,Reinhard F,Zhang CC,Shipitsin M,Campbell LL,Polyak K,Brisken C,Yang J,Weinberg RA.The epithelial-mesenchymal transition generates cells with properties of stem cells.Cell. 2008;133:704-15.
12. Dalerba P,Cho RW,Clarke MF.Cancer stem cells: models and concepts.Annu Rev Med. 2007;58:267-84.
13. Engelen E,Akinci U,Bryne JC,Hou J,Gontan C,Moen M,Szumska D,Kockx C,van Ijcken W,Dekkers DH,Demmers J,Rijkers EJ,Bhattacharya S,Philipsen S,Pevny LH,Grosveld FG,Rottier RJ,Lenhard B,Poot RA.Sox2 cooperates with Chd7 to regulate genes that are mutated in human syndromes.Nat Genet. 2011;43:607-11.
14. Arumugam T,Ramachandran V,Fournier KF,Wang H,Marquis L,Abbruzzese JL,Gallick GE,Logsdon CD,McConkey DJ,Choi W.Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.Cancer Res. 2009;69:5820-28.
15. Siebzehnrubl FA,Silver DJ,Tugertimur B,Deleyrolle LP,Siebzehnrubl D,Sarkisian MR,Devers KG,Yachnis AT,Kupper MD,Neal D,Nabilsi NH,Kladde MP,Suslov O,Brabletz S,Brabletz T,Reynolds BA,Steindler DA.The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance.EMBO Mol Med. 2013;5:1196-1212.